ASH 2021 | Genomic profiling of smoldering myeloma to improve risk stratification models
Irene Ghobrial
• 11 Dec 2021
In this video, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, highlights the importance of clinical markers and risk stratification models in smoldering myeloma, and how these models can be improved. Dr Ghobrial discusses the benefits of genomic profiling of smoldering myeloma using methods such as whole exome sequencing and RNA sequencing, and how this data can help doctors monitor disease progression and allow for early detection of patient risk for developing multiple myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
